Evidence map›Paper›PMID 40741952›Full record

ArticleAntimicrobial agents and chemotherapy2025

A rational approach to discovering new persister control agents.

Sweta Roy, Zeynep S Cakmak, Sheila Priscilla Kyeremeh, Shikha Nangia, Juntao Luo, Dacheng Ren

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mini review: Persister cell control strategies.Frontiers in pharmacology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sweta RoyDepartment of Biomedical and Chemical Engineering, Syracuse University, Syracuse, New York, USA.ORCID 0000-0002-6266-1598
Zeynep S CakmakDepartment of Biomedical and Chemical Engineering, Syracuse University, Syracuse, New York, USA.
Sheila Priscilla KyeremehDepartment of Biomedical and Chemical Engineering, Syracuse University, Syracuse, New York, USA.ORCID 0009-0006-2209-0942
Shikha NangiaDepartment of Biomedical and Chemical Engineering, Syracuse University, Syracuse, New York, USA.
Juntao LuoDepartment of Pharmacology, State University of New York Upstate Medical University, Syracuse, New York, USA.ORCID 0000-0002-3538-9453
Dacheng RenDepartment of Biomedical and Chemical Engineering, Syracuse University, Syracuse, New York, USA.ORCID 0000-0002-6517-906X

Funding

A 800 MHz Nuclear Magnetic Resonance Spectrometer in Support of Life Science ReseS10OD012254 · OD · UPSTATE MEDICAL UNIVERSITY · PI WILKENS, STEPHAN · 2013 to 2013
$2.0M
Controlling Catheter-Associated Urinary Tract Infections Using Smart Catheters with Rationally Designed Active TopographiesR01EB030621 · NIBIB · SYRACUSE UNIVERSITY · PI REN, DACHENG · 2021 to 2024
$1.5M
NIBIB NIH HHS R01 EB030621NIH HHS 1R01EB030621NIH HHS S10 OD012254
6 · The paper itself

Abstract

Conventional antibiotic drug discovery selects leads based on bacterial growth inhibition. This approach is ineffective against growth-arrested persister cells. When the treatment stops, persister cells revert to normal cells, causing the infection to relapse. To address the challenge of persistent infections, a paradigm shift in antibiotic development is needed to identify new leads that can eradicate dormant cells. Based on our foundational study, we recently proposed a set of principles for developing new persister killing agents. Here, we report the discovery of new leads that are effective against persister cells using a tailored chemoinformatic clustering algorithm based on these principles. We focused on persister penetration using a small compound library that has known antimicrobial activities against normal cells. Experimental testing of eleven compounds identified from clustering led to the discovery of five new compounds that can effectively penetrate and kill persister cells of

Indexed as

Anti-Bacterial AgentsDrug DiscoveryPseudomonas aeruginosaUropathogenic Escherichia coliAlgorithmsBiofilmsEscherichia coliHumansMicrobial Sensitivity TestsSmall Molecule LibrariesAnti-Bacterial AgentsSmall Molecule Librarieschemoinformaticclusteringdrug discoverykillingpersister

Identifiers

PMID40741952
PMCPMC12406675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.